Driveline Infection in Patients With Left Ventricular Assist Devices Implanted as Destination Therapy

Grzegorz Wasilewski; Sylwia Wiśniowska-Śmiałek; Izabela Górkiewicz-Kot; Irena Milaniak; Michał Kaleta; Hubert Hymczak; Agata Wasilewska; Karol Wierzbicki

doi:10.1016/j.transproceed.2024.03.029

Driveline Infection in Patients With Left Ventricular Assist Devices Implanted as Destination Therapy

Transplant Proc. 2024 May 10:S0041-1345(24)00203-3. doi: 10.1016/j.transproceed.2024.03.029. Online ahead of print.

Authors

Grzegorz Wasilewski¹, Sylwia Wiśniowska-Śmiałek², Izabela Górkiewicz-Kot², Irena Milaniak², Michał Kaleta², Hubert Hymczak², Agata Wasilewska³, Karol Wierzbicki²

Affiliations

¹ Department of Cardiovascular Surgery and Transplantology, Jagiellonian University, Medical College, John Paul II Hospital, Cracow, Poland. Electronic address: grzegorz.wa@interia.pl.
² Department of Cardiovascular Surgery and Transplantology, Jagiellonian University, Medical College, John Paul II Hospital, Cracow, Poland.
³ Department of Pediatric and Gastroenterology, Jagiellonian University, Medical College, Cracow, Poland.

PMID: 38734518
DOI: 10.1016/j.transproceed.2024.03.029

Abstract

Background: Donor organ shortages cause increasing demand for mechanical circulatory support in patients with end-stage heart failure not only as a bridge to heart transplantation but mainly as a destination therapy. Improved results and increased applicability and durability of left ventricular assist devices (LVADs) have established this treatment option as an alternative to heart transplantation in selected patients. One of the most common complications after LVAD implantation is driveline infections (DLIs).

Methods: This study aimed to expand the understanding of DLI epidemiology and potential changes in implantation techniques regarding optimizing DLI prevention and treatment among all patients undergoing LVAD (Medtronic's Heartware HVAD and HeartMate 3 Abbott LVAD system) implantation with at least 12 months of follow-up time between 2015 and 2022.

Results: There were 120 individuals with LVAD implantation, of whom 90 had 12 months of follow-up (85 men [94%], 5 women [6%]) with a median age of 58 years (50.25-63.75). The median body mass index was 27.12 kg/m² (25.27-29.68). Of the 90 patients, 43 had ischemic heart failure (48%), 43 had dilated cardiomyopathy (48%), and the remaining 3 had other etiologies (3%), such as postinflammatory, and the remaining 1 had congenital heart defect (1%). Preoperative echocardiography revealed a mean left ventricle ejection fraction of 13.8% and a median left ventricle dimension of 7.55 cm (6.92-8.2). Imaging confirmed pulmonary hypertension in 61 patients (68%). Thirty-four of the 90 patients had diabetes (38%), and 16 were active smokers (18%). Median follow-up was 30 months (17.25-42), with the longest period being 82 months. More than half of the patients (n = 52; 57%) experienced a DLI. The median time to the first episode of DLI was 13 months (6-25). The most common pathogen revealed in wound swab culture was methicillin-sensitive Staphylococcus aureus (n = 23; 44%), Pseudomonas aeruginosa (n = 9; 17%), Proteus mirabilis (n = 4; 7%), and others. We observed that deeper driveline implantation below the left rectus muscle and just above the posterior rectus sheath resulted in fewer DLIs and longer free-from-DLI follow-up time. There was no statistically significant difference in DLI frequency between patients with or without diabetes mellitus.

Conclusions: Appropriate selection of candidates and timing of LVAD implantation are critical for improved outcomes of destination therapy. DLI is the most common complication after LVAD implantation. Optimal surgical techniques and early implementation of targeted antibiotics are crucial. Significant challenges remain in optimizing DLI prevention and treatment.